 Source: Bukhta Yurii Shutterstock.com Karuna Therapeutics NASDAQ: KRTX stock is rocketing higher on Monday thanks to results from its Phase 3 EMERGENT-2 trial. This trial covers the efficacy, safety, and tolerability of KarXT in adults suffering from schizophrenia. 